Use of statistical analysis to monitor novel coronavirus-19 cases in Jammu and Kashmir, India

  • Digvijay Pandey Department of Technical Education, IET, Lucknow, India
  • Tajamul Islam Department of Botany, University of Kashmir, Srinagar-190006, J & K, India
  • Junaid A. Magray Department of Botany, University of Kashmir, Srinagar-190006, J & K, India
  • Aadil Gulzar Department of Environmental Science, University of Kashmir, Srinagar-190006, J & K, India
  • Shabir A. Zargar Department of Botany, University of Kashmir, Srinagar-190006, J & K, India
Keywords: Clusters, Coronavirus, SARS-CoV-2, Districts, Jammu and Kashmir, Similarities


Coronavirus disease (COVID-19) has been increasing slowly and steadily in all the districts of Jammu and Kashmir, India. It is essential for the government and health management system to monitor the districts affected due to COVID-19. The main objective of this study is to ascertain and categorize the COVID-19 affected districts into real clusters based on similarities within a cluster and differences among clusters in order to imply standard operating procedures (SOPs) policies, decisions, medical facilities, etc. could be improved for reducing the risk of infection and death and optimize the deployment of resources for preventing subsequent outbreaks.



Download data is not yet available.


1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497-506.
2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020; 382(8): 727-733.
3. Bai Y, Yao L, Wei T, Tian F, Jin DY, Chen L. et al. Presumed asymptomatic carrier transmission of COVID-19. Jama. 2020; 323(14): 1406-1407.
4. Phan LT, Nguyen TV, Luong QC, Nguyen TV, Nguyen HT, Le HQ, et al. Importation and Human-to-Human Transmission of a Novel Coronavirus in Vietnam. N Engl J Med. 2020; 382(13): 1199-1207.
5. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical characteristics of coronavirus disease 2019 in China. New Engl J Med. 2020; 382(18): 1708-1720.
6. Giovanetti M, Benvenuto D, Angeletti S, Ciccozzi M. The first two cases of 2019-nCoV in Italy: Where they come from? J Med Virol. 2020; 92: 518-521.
7. World Health Organization. Statement on the second meeting of the International Health Regulations (2005) Emergency Committee regarding the outbreak of novel coronavirus (2019-nCoV).
8. Rather RA, Islam T, Rehman IU, Pandey D. Development of vaccine against coronavirus disease-2019 (COVID-19) in India. Asian J Adv Med Sci. 2021; 3(2): 13-21.
9. Zumla A, Chan JF, Azhar EI, Hui DSC, Yuen KY. Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016; 15(5): 327‐347.
10. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan. China Lancet 2020; 395(10223): 497-506.
11. Chan JF, Lau SK, Woo PC. The emerging novel Middle East respiratory syndrome coronavirus: the “knowns” and “unknowns”. J Formos Med Assoc. 2013; 112(7): 372‐381.
12. Channappanavar R, Zhao J, Perlman S. T cell‐mediated immune response to respiratory coronaviruses. Immunol Res. 2014; 59(1‐3): 118‐128.
13. Cheng VC, Lau SK, Woo PC, Yuen KY. Severe acute respiratory syndrome coronavirus as an agent of emerging and reemerging infection. Clin Microbiol Rev. 2007; 20(4): 660‐694.
14. Chan JF, Lau SK, To KK, Cheng VC, Woo PC, Yuen KY. Middle East respiratory syndrome coronavirus: another zoonotic betacoronavirus causing SARS‐like disease. Clin Microbiol Rev. 2015; 28(2): 465‐522.
15. Gretebeck LM, Subbarao K. Animal models for SARS and MERS coronaviruses. Curr Opin Virol. 2015; 13: 123‐129.
16. Gralinski LE, Baric RS. Molecular pathology of emerging coronavirus infections. J Pathol. 2015; 235(2): 185‐195.
17. Drosten C, Günther S, Preiser W, van der Werf S, Brodt HR, Becker S, et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med. 2003; 348(20): 1967‐1976.
18. Liu J, Zheng X, Tong Q, Li W, Wang B, Sutter K, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS‐CoV, MERS‐CoV, and 2019‐nCoV. J Med Virol. 2020; 92(5): 491‐494.
19. Zargar SA, Islam T, Rehman IU, Pandey D. Use of Cluster Analysis To Monitor Novel Corona Virus (Covid-19) Infections In India. Asian J Adv Med Sci. 2021; 3(2): 1-7.
20. COVID-19 Monitoring Dashboard maintained by Ministry of Health and Family Welfare Government of India (GoI). Available from Accessed on 5 January 2021.
21. Dilts D, Khamalah J, Plotkin A. Using cluster analysis for medical resource decision making. Med Decis Mak. 1995; 15: 333-347.
22. McLachlan GJ. Cluster analysis and related techniques in medical research. Stat Methods Med Res. 1992; 1: 27-48.
23. Borgen FH, Barnett DC. Applying cluster analysis in counseling psychology research. J Counsel Psychol. 1987; 34(4): 456.
24. Johnson RA, Wichern DW. 2002. Applied multivariate statistical analysis (Vol. 5, No. 8). Upper Saddle River, NJ: Prentice hall.
25. Kumar S. Use of cluster analysis to monitor novel coronavirus-19 infections in Maharashtra, India. Indian J Med Sci. 2020; 72(2): 44.
26. Das S. Prediction of COVID-19 disease progression in India: Under the effect of national lockdown. 2020;
27. Ray D, Salvatore M, Bhattacharyya R, Wang L, Du J, Mohammed S, et al. Predictions, Role of Interventions and Effects of a Historic National Lockdown in India’s Response to the the COVID-19 Pandemic: Data Science Call to Arms. Harvard Data Sci Rev. 2020;
How to Cite
Pandey, D.; Islam, T.; Magray, J.; Gulzar, A.; Zargar, S. Use of Statistical Analysis to Monitor Novel Coronavirus-19 Cases in Jammu and Kashmir, India. European Journal of Biological Research 2021, 11, 274-282.
Research Articles